Results 111 to 120 of about 28,422 (269)

Kinetics of Antibody Responses and Effector Cell Sensitivity After High Dose Birch Extract Nasal Challenge

Allergy, EarlyView.
High‐dose birch‐extract nasal challenge induced synchronous peaks at 4 weeks in serum specific IgE (sIgE) and basophil sensitivity. Mast cell sensitivity via tSPT and sIgG1 and sIgG4 responses peaked later, at 6–8 weeks. Preseasonal allergen exposure attenuated seasonal sIgE increase and prevented further rise in tSPT sensitivity.
N. J. Campion, S. Villazala‐Merino, C. Morgenstern, L. Nemec, V. Stanek, A. Tu, M. Zghaebi, J. Toth, R. Fröschl, T. Perkmann, M. Bastl, K. Gangl, S. Schneider, H. Breiteneder, R. Ristl, M. Focke‐Tejkl, R. Valenta, V. Niederberger‐Leppin, J. Eckl‐Dorna   +18 more
wiley   +1 more source

Efficacy and safety of omalizumab for the treatment of refractory chronic spontaneous urticaria in Japanese patients: Subgroup analysis of the phase 3 POLARIS study

Allergology International, 2018
Background: Omalizumab, a humanized anti-IgE monoclonal antibody, proved efficacious and well tolerated in patients with chronic spontaneous urticaria (CSU) refractory to H1 antihistamines (H1AH) in the POLARIS study (NCT02329223), a randomized, double ...
Michihiro Hide, Atsuyuki Igarashi, Akiko Yagami, Yuko Chinuki, Naoko Inomata, Atsushi Fukunaga, Guenther Kaiser, Junyi Wang, Soichiro Matsushima, Steven Greenberg, Sam Khalil   +10 more
doaj   +1 more source

Omalizumab for Severe Allergic Asthma Treatment in Italy: A Cost-Effectiveness Analysis from PROXIMA Study

Risk Management and Healthcare Policy, 2020
Giorgio Walter Canonica, 1 Giorgio Lorenzo Colombo, 2, 3 Paola Rogliani, 4 Pierachille Santus, 5 Claudia Pitotti, 6 Sergio Di Matteo, 3 Chiara Martinotti, 3 Giacomo Matteo Bruno 3 1Asthma & Allergy Clinic, Humanitas University, Milan, Italy; 2S.A.V.
Canonica GW, Colombo GL, Rogliani P, Santus P, Pitotti C, Di Matteo S, Martinotti C, Bruno GM   +7 more
doaj  

Cost Utility of Omalizumab Compared with Standard of Care for the Treatment of Chronic Spontaneous Urticaria. [PDF]

, 2016
BACKGROUND: Chronic spontaneous urticaria (CSU) negatively impacts patient quality of life and productivity and is associated with considerable indirect costs to society.
Agirrezabal, I., Alexopoulos, S.T., Balp, M.M., Brennan, A., Graham, J., Griffiths, M., Halliday, A., McBride, D., Stull, D., Zuberbier, T.   +9 more
core   +1 more source

Unveiling Rare Genetic Variants in DAB2IP: New Insights Into the Pathogenesis of Recurrent Angioedema

Allergy, EarlyView.
Maurizio Margaglione, Maria D'Apolito, Rosa Santacroce, Giorgia Cordisco, Francesco Arcoleo, Tiziana De Pasquale, Ilaria Puxeddu, Andrea Zanichelli, Mauro Cancian   +8 more
wiley   +1 more source

Is Asthma Remission a New Achievable Goal? A Review of the Current Drug‐Related Evidence and Predictors

Allergy, EarlyView.
ABSTRACT Advances in asthma therapies have shown that clinical remission may be an achievable therapeutic goal for patients with asthma. This review discusses the current definitions of remission in asthma, the predictors of remission, airway inflammation/epithelial damage in asthma remission, airway remodeling, paradigms in defining remission and ...
Fatma Esra Gunaydin, Giulia Marcassa, Bianca Olivieri, Gianenrico Senna, Marco Caminati   +4 more
wiley   +1 more source

Case Report: Resolution of chronic urticaria following treatment of odontogenic infection. [PDF]

, 2019
Background: Chronic spontaneous urticaria (CSU) is a condition characterised by the presence of hives with/without angioedema, that affects individuals on more days than not for 6 weeks or more.
Bahal, S, Nagendran, V, Tadros, S
core   +1 more source

Effectiveness and Predictors of House Dust Mite Subcutaneous Immunotherapy in Polysensitised Patients With Allergic Rhinitis: A Multicentre Retrospective Study

Clinical &Experimental Allergy, EarlyView.
Single‐allergen dust mite subcutaneous immunotherapy achieved 68.8% perennial symptom response rate in polysensitised allergic rhinitis patients. High mould and dust mite sIgE levels predicted poor allergen immunotherapy response, which indicated allergen‐specific sIgE levels may help guide personalised allergen immunotherapy decisions.
Zhouxian Pan, Shengyang Yao, Lisha Li, Yongshi Yang, Wenchao Guan, Yin Wang, Xiaoshang Lou, Chuanhe Liu, Yanmin Bao, Shijie Zhuang, Li Sha, Ruonan Chai, Rongfei Zhu, Kai Guan   +13 more
wiley   +1 more source

Omalizumab for Chronic Urticaria: A Case Series and Overview of the Literature

Case Reports in Dermatology, 2012
Omalizumab is a recombinant humanized monoclonal antibody that blocks the high-affinity Fc receptor of IgE. Omalizumab has been approved for the treatment of moderate to severe asthma; however, there is currently more and more data showing promising ...
Ilya Ivyanskiy, Carsten Sand, Simon Francis Thomsen   +2 more
doaj   +1 more source

Precision Medicine in Targeted Therapies for Severe Asthma:Is There Any Place for "omics" Technology? [PDF]

, 2018
According to the current guidelines, severe asthma still represents a controversial topic in terms of definition and management. The introduction of novel biological therapies as a treatment option for severe asthmatic patients paved the way to a ...
Bertolini, Francesca, Caminati, Marco, Facciolongo, Nicola, Galeone, Carla, Menzella, Francesco, Ruggiero, Patrizia, Scelfo, Chiara   +6 more
core   +2 more sources